Primary Prevention of Cardiovascular Disease with Statins in the Elderly
- 988 Downloads
Owing to the progressive aging of the population, and the fact that cardiovascular disease (CVD) is the leading cause of death among the elderly, the prevention of CVD in the elderly is becoming increasingly important. Although there is no doubt that statin treatment should be used for reducing CVD risk in the elderly in secondary prevention in the same way as in younger individuals, the evidence that such treatment really prolongs life in elderly subjects in primary prevention is still not so clear. However, it seems that it does reduce CVD morbidity in elderly individuals. Because of limited evidence regarding the benefit of such therapy, particularly in very old subjects (older than 80–85 years), the decision whether to treat or not treat an elderly individual with statins in primary prevention should be based on good clinical judgment and considering the individual subject’s situation regarding comorbidities, polypharmacy, and possible adverse effects.
KeywordsCardiovascular disease Statins Elderly LDL-cholesterol Adverse effects Guidelines
Compliance with Ethics Guidelines
Conflict of Interest
Željko Reiner has received personal fees from Abbott, AstraZeneca, and Merck, and grants and personal fees from Sanofi.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 13.••Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818. These are the first European guidelines for the management of dyslipidemias containing an important section on the treatment of dyslipidemias in the elderly.PubMedCrossRefGoogle Scholar
- 14.Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701.PubMedCrossRefGoogle Scholar
- 15.••Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi: 10.1161/01.cir.0000437738.63853.7a. These are the most recent US guidelines on the treatment of hypercholesterolemia, mentioning also the treatment of the elderly.PubMedCentralGoogle Scholar
- 16.Ray KK, Kastelein JJP, Boekholdt SM, Nicholls SJ, Khaw K-T, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults - the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014; doi 10.1093/eurheartj/ehu107
- 19.National Heart, Blood, and Lung Institute. NHLBI, estimate of 10-year risk for CHD. http://www.nhlbi.nih.gov/guidelines/cholesterol/risk_tbl.htm. Accessed February 14, 2014.
- 20.Zannad F, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L, De Backer G, et al. Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) workshop of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy. Eur J Prev Cardiol. 2012;19(6):1454–64.PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.PubMedCrossRefGoogle Scholar
- 25.Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.PubMedCrossRefGoogle Scholar
- 26.Nakaya N, Mizuno K, Ohashi Y, Teramoto T, Yokoyama S, Hirahara K, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging. 2011;28(9):681–92.PubMedCrossRefGoogle Scholar
- 27.Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med. 2002;162(12):1395–400.PubMedCrossRefGoogle Scholar
- 29.Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–96.PubMedCentralPubMedCrossRefGoogle Scholar
- 31.••Savarese G, Gotto Jr AM, Paolillo S, D'Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090–9. This article provides very recent data showing that in elderly subjects at high CVD risk but without established CVD, statins significantly reduce the incidence of myocardial infarction and stroke, but do not significantly prolong survival in the short term.PubMedCrossRefGoogle Scholar
- 34.Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Can J Cardiol. 2011 Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Canad. J Cardiol. 2011;27(5):635–62.Google Scholar
- 40.Younoszai Z, Li Z, Stepanova M, Erario M, Cable R, Younossi ZM. Statin use is not associated with liver related mortality. Ann Hepatol. 2013–2014;13(1):84–90.Google Scholar
- 42.Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134(10):931–40.PubMedCrossRefGoogle Scholar
- 44.Cholesterol Treatment Trialists’ (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE. 2012;7(1):e29849.PubMedCrossRefGoogle Scholar